Dryness (CST 250 – 325) Anti-IL-6 Vamikibart 0.25 mg 1 mg 0.25 mg 1 mg MEERKAT 2 SANDCAT 2 APEX 3 Anti-IL-6, VEGF trap KSI-101 DOVETAIL 1 0.25 mg 1 mg 2.5 mg Mean Change in OCT CST and Absolute CST OCT CST (μm) OCT CST (μm) 250 300 350 400 450 500 550 250 300 350 400 450 500 550 For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Day 1 Week 1 Week 4 Week 8 Week 12 Week 16 Day 1 Week 1 Week 4 Week 8 Week 12 Week 16 n-values at baseline. 1. Adapted from Sharma S, et al. Phase 1 DOVETAIL Study. Presented at the American Society of Retina Specialists, Seattle, WA, July 2023. Note DOVETAIL had only 3 loading doses. 2. Adapted from Khurana, et al. Phase 3 MEERKAT and SANDCAT. Presented at the American Academy of Ophthalmology Retina Subspecialty Day, Orlando, FL, October 17, 2025. 3. Preliminary results. 3. The APEX study is ongoing. Final results may be different due to data cleaning. Results include patients in the per protocol set that met all eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). n=74 n=78 n=85 n=86 n=12 n=12 n=13 2.5 mg 5 mg 10 mg n=12 n13 n=13 53